Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) Starts Presentation at 29th Annual Roth Conference
Sucampo Pharmaceuticals (NASDAQ: SCMP) is a biopharmaceutical company that focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the United States, Japan, Switzerland and internationally. The company’s marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. For more information, visit the company’s website at www.sucampo.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release…







